Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

NCT06040177 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable
Portal Vein Tumor Thrombus
Immune Checkpoint Inhibitors

Interventions

DRUG: Cadonilimab
RADIATION: Stereotactic radiotherapy
DRUG: Renvatinib

Sponsor

First Affiliated Hospital of Guangxi Medical University